NASDAQ:GTXI - GTX Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.16 -0.03 (-2.52 %) (As of 12/18/2018 06:22 AM ET)Previous Close$1.19Today's Range$1.14 - $1.2052-Week Range$1.14 - $25.60Volume245,597 shsAverage Volume357,166 shsMarket Capitalization$28.62 millionP/E Ratio-0.66Dividend YieldN/ABeta1.6 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee. Receive GTXI News and Ratings via Email Sign-up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:GTXI Previous Symbol CUSIP40052B10 Webwww.gtxinc.com Phone901-523-9700 Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32 Price-To-Earnings Trailing P/E Ratio-0.66 Forward P/E Ratio-0.70 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book0.65 Profitability EPS (Most Recent Fiscal Year)($1.75) Net Income$-30,430,000.00 Net MarginsN/A Return on Equity-126.41% Return on Assets-100.34% Miscellaneous Employees27 Outstanding Shares24,050,000Market Cap$28.62 million OptionableOptionable GTX (NASDAQ:GTXI) Frequently Asked Questions What is GTX's stock symbol? GTX trades on the NASDAQ under the ticker symbol "GTXI." How were GTX's earnings last quarter? GTx, Inc. (NASDAQ:GTXI) issued its earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.09. View GTX's Earnings History. When is GTX's next earnings date? GTX is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for GTX. What price target have analysts set for GTXI? 2 brokers have issued 12 month price targets for GTX's shares. Their predictions range from $17.00 to $45.00. On average, they anticipate GTX's share price to reach $31.00 in the next year. This suggests a possible upside of 2,572.4% from the stock's current price. View Analyst Price Targets for GTX. What is the consensus analysts' recommendation for GTX? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GTX in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GTX. Has GTX been receiving favorable news coverage? Media stories about GTXI stock have trended negative recently, InfoTrie reports. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. GTX earned a media sentiment score of -2.4 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the stock's share price in the near future. Who are some of GTX's key competitors? Some companies that are related to GTX include DURECT (DRRX), Mersana Therapeutics (MRSN), Sol Gel Technologies (SLGL), Spero Therapeutics (SPRO), Sesen Bio (SESN), Cue Biopharma (CUE), Selecta Biosciences (SELB), Sierra Oncology (SRRA), BELLUS Health (BLUSF), Chembio Diagnostics (CEMI), Tiziana Life Sciences (TLSA), Iterum Therapeutics (ITRM), Eton Pharmaceuticals (ETON), PhaseBio Pharmaceuticals (PHAS) and Vernalis (VNLPY). Who are GTX's key executives? GTX's management team includes the folowing people: Dr. Robert James Wills Ph.D., Exec. Chairman (Age 64)Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 55)Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 69)Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 43)Dr. Diane C. Young, VP & Chief Medical Officer (Age 61) Who are GTX's major shareholders? GTX's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (2.00%), Vanguard Group Inc (1.94%), Vanguard Group Inc. (1.94%), Bridgeway Capital Management Inc. (1.14%), Candriam Luxembourg S.C.A. (1.09%) and Vivo Capital LLC (0.44%). Company insiders that own GTX stock include Diane C Young, Henry Patton Doggrell, Jason T Shackelford, Marc Steven Hanover and Robert James Wills. View Institutional Ownership Trends for GTX. Which institutional investors are buying GTX stock? GTXI stock was acquired by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Candriam Luxembourg S.C.A., Vivo Capital LLC, BlackRock Inc., Vanguard Group Inc and Vanguard Group Inc.. View Insider Buying and Selling for GTX. How do I buy shares of GTX? Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is GTX's stock price today? One share of GTXI stock can currently be purchased for approximately $1.16. How big of a company is GTX? GTX has a market capitalization of $28.62 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe. What is GTX's official website? The official website for GTX is http://www.gtxinc.com. How can I contact GTX? GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected] MarketBeat Community Rating for GTX (NASDAQ GTXI)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 192 (Vote Outperform)Underperform Votes: 172 (Vote Underperform)Total Votes: 364MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: What is Compound Annual Growth Rate (CAGR)?